Imfinzi (durvalumab) is an antibody pharmaceutical. Durvalumab was first approved as Imfinzi on 2017-05-01. It is used to treat transitional cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against programmed cell death 1 ligand 1.
|Indication||non-small-cell lung carcinoma, transitional cell carcinoma|
|Drug Class||Monoclonal antibodies: fully human, immunomodulating|